Results 41 to 50 of about 2,579 (176)

Ravulizumab in NMOSD with associated interstitial pneumonitis in a 59-year-old female patient: a case report [PDF]

Frontiers in Immunology
IntroductionNeuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system often associated with aquaporin-4-immunoglobulin-G (AQP4-IgG), which activate the complement system, and it can lead to progressive ...
Andrea Neundorf, Ralf Dittrich
doaj   +2 more sources

One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab [PDF]

, 2021
Ravulizumab every 8 weeks showed non-inferiority to eculizumab every 2 weeks in a 26-week, phase 3, randomized controlled trial in adults with paroxysmal nocturnal hemoglobinuria (PNH) who were clinically stable on eculizumab (NCT03056040).
Masayo Ogawa, Stephan Ortiz, Ogawa, M., Emilio Ojeda Gutierrez, Röth, Alexander, Gutierrez, E., Lee, J.W.L., Mitchell, Lindsay, Kensuke Usuki, F. Ataúlfo González Fernández, Caroline I. Piatek, Gaya, A., Piatek, C.I., Anna Gaya, Mitchell, L., Austin G. Kulasekararaj, Brodsky, Robert A, Alexander Röth, Langemeijer, Saskia, Peffault de Latour, Régis, Lindsay Mitchell, Bosi, Alberto, Yu, J., Brodsky, R.A., Régis Peffault de Latour, Wells, R., Ojeda Gutierrez, Emilio, Langemeijer, S.M., Robert A. Brodsky, Saskia Langemeijer, Alberto Bosi, Röth, A., Usuki, K., Wells, Richard, Lee, Jong Wook, Gaya, Anna, Ji Yu, Ortiz, S., Anita Hill, Jong Wook Lee, Kulasekararaj, Austin G, Kulasekararaj, A.G., Peffault de Latour, R., Piatek, Caroline I, Usuki, Kensuke, Ortiz, Stephan, Yu, Ji, Gonzalez Fernandez, F.A., Richard Wells, Hill, Anita, Ogawa, Masayo, Hill, A., Bosi, A., González Fernández, F Ataúlfo   +53 more
core   +1 more source

Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder [PDF]

, 2023
OBJECTIVE: CHAMPION-NMOSD (NCT04201262) is a phase 3, open-label, externally controlled interventional study evaluating the efficacy and safety of the terminal complement inhibitor ravulizumab in adult patients with anti-aquaporin-4 antibody-positive ...
Berthele, A., Nakashima, I., Pittock, S.J., Oreja-Guevara, C., Paul, F., Yountz, M., Mashhoon, Y., Kim, H.J., Palace, J., de Seze, J., Pozzilli, C., Levy, M., Bennett, J.L., Barnett, M., Allen, K., Jeffrey L. Bennett, Marcus Yountz, Yasmin Mashhoon, Ho Jin Kim, Pittock, Sean J.;Barnett, Michael;Bennett, Jeffrey L.;Berthele, Achim;de Sèze, Jérôme;Levy, Michael;Nakashima, Ichiro;Oreja‐Guevara, Celia;Palace, Jacqueline;Paul, Friedemann;Pozzilli, Carlo;Yountz, Marcus;Allen, Kerstin;Mashhoon, Yasmin;Kim, Ho Jin, Sean J. Pittock, Jacqueline Palace, Michael Levy, Michael Barnett, Jérôme de Sèze, Friedemann Paul, Celia Oreja‐Guevara, Kerstin Allen, Achim Berthele, Ichiro Nakashima, Carlo Pozzilli   +30 more
core   +2 more sources

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. [PDF]

Eur J Neurol
ABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals ...
Meisel A, Marina AD, Doksani P, Hagenacker T, Kleinschnitz C, Krämer HH, Lünemann JD, Meuth SG, Ruck T, Schara-Schmidt U, Schneider-Gold C, Schoser B, Schroeter M, Schubert C, Sieb JP, Zimprich F, Zschüntzsch J, Hoffmann S.   +17 more
europepmc   +2 more sources

Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial [PDF]

Key Points This phase 2, double-blind, randomized controlled trial evaluated the complement C5 inhibitor, ravulizumab, in adults with IgA nephropathy.
Tumlin, James, Pérez Valdivia, Miguel Ángel, Fenoglio, Roberta, Barratt, Jonathan, Susan Huang, Shih-Han, Garlo, Katherine, Kim, Sung Gyun, Kateifides, Andreas, Kaufeld, Jessica, Rice, Kara, Wu, Mai-Szu, Alamartine, Eric, Yee, Min, The SANCTUARY Study Investigators, Lafayette, Richard   +14 more
core   +3 more sources

Ravulizumab for the treatment of myasthenia gravis

Expert Opinion on Biological Therapy, 2023
Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on nonselective immunosuppression with oral steroids and non-steroidal immunosuppressants, mainly with good clinical response.
Vanoli Fiammetta, Renato Mantegazza
openaire   +3 more sources

Ravulizumab in pregnancy: the case for cautious optimism. [PDF]

Blood Adv
Shammo JM.
europepmc   +2 more sources

Ravulizumab (Ultomiris)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +2 more sources

Cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab maintenance treatment

eJHaem, 2022
A 47‐year‐old male with paroxysmal nocturnal haemoglobinuria (PNH) controlled with routine ravulizumab administration suffered a massive haemolytic crisis due to choledocholithiasis.
Mitsuru Moriyama, Yasuo Aota, Masahiro Okabe, Yoshiaki Osaka, Seiichiro Katagiri, Daigo Akahane, Akihiko Gotoh   +6 more
doaj   +1 more source

Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

BMC Nephrology, 2021
Background Atypical hemolytic uremic syndrome (aHUS) triggered by pregnancy is a rare disease caused by dysregulation of the alternative complement pathway that occurs in approximately 1 in 25,000 pregnancies.
Anja Gäckler, Ulf Schönermarck, Vladimir Dobronravov, Gaetano La Manna, Andrew Denker, Peng Liu, Maria Vinogradova, Sung-Soo Yoon, Manuel Praga   +8 more
doaj   +1 more source